Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Solid Tumor: early-phase trial registry
133 of 190 indexed Advanced Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #56 of 28,707 conditions by registered trial count.
190 US clinical trials · 133 currently recruiting · #56 of 28,707 conditions by registered trial count
Advanced Solid Tumor: 190 US clinical trials tracked, 133 recruiting.
Advanced Solid Tumor is the subject of 190 registered US clinical trials on ClinicalTrials.gov, 133 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 186 in Phase 1-2 (earlier-stage). The most active sponsor is Daiichi Sankyo, running 7 of these trials.
Enrollment posture brief
Registry condition advanced-solid-tumor
OPEN 133 | RECR 70% | LATE 0 | EARLY 186 | RANK #56 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Anatomic Stage IV Breast Cancer AJCC v8 (70% recruiting · 60 trials)
Advanced Solid Tumor lists 133 open slots (70% of 190 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Solid Tumor is recruiting above its size-band peers.
133 of 190 indexed trials (70%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Advanced Solid Tumor trials is spread across many organizations.
Daiichi Sankyo accounts for 7 of 190 trials (3.7%). 135 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Solid Tumor enrolment sits around 141 participants.
Median target enrolment is 141 among the 190 trials that report a genuine target (sentinel values excluded). 73 of those (38.4%) plan for fewer than 100 participants.
-
Advanced Solid Tumor research is mostly interventional.
188 interventional and 2 observational studies make up this index (98.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
190 total, page 1 of 4
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
University of Chicago
NCT05166694
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
DualityBio
NCT05438329
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
DualityBio
NCT05785741
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
BioNTech SE
NCT07070232
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT06172478
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT05875168
AIMS Cancer Outcomes Study
Advanced Integrative Medical Science Institute
NCT04495790
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06238479
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
CStone Pharmaceuticals
NCT05279300
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
Debiopharm International
NCT04855656
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics
NCT05867251
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Exelixis
NCT05932862
A Study of YL242 in Subjects With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co.
NCT07197827
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
Selecxine
NCT05525247
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company
NCT06465069
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
Gilead Sciences
NCT05007782
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Synthekine
NCT05098132
XTX301 in Patients With Advanced Solid Tumors
Xilio Development
NCT05684965
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation
NCT05824975
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
NCT06241456
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
NCT06561685
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Bristol-Myers Squibb
NCT05245500
A Study in Patients With Advanced Cancers
BiOneCure Therapeutics
NCT05320588
A Study of PYX-201 in Advanced Solid Tumors
Pyxis Oncology
NCT05720117
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
GI Innovation
NCT04977453
A Study of YL201 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co.
NCT05434234
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
NCT06233942
Study in Advanced Solid Tumor Patients
Callio Therapeutics
NCT07300943
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeiGene
NCT06120283
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals
NCT04585750
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
NCT04104776
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Ellipses Pharma
NCT05443126
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
SillaJen
NCT05768932
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT06257264
Evaluate the Safety and Clinical Activity of HH2853
Haihe Biopharma Co.
NCT04390737
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Daiichi Sankyo
NCT04145622
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
NCT06242470
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
BeOne Medicines
NCT06589596
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
TiumBio Co.
NCT05204862
A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)
Anaveon
NCT06470763
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co.
NCT06707610
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
NCT06997029
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co.
NCT06859762
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06545942
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
NCT06577987
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
NCT05981703
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS
NCT06597721
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Daiichi Sankyo
NCT06244485
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
OncoC4
NCT06635785
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Daiichi Sankyo
NCT06660654
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 180 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Solid Tumor page
190 registered trials, 133 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 133 Advanced Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Daiichi Sankyo sponsors the most Advanced Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Daiichi Sankyo's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Solid Tumor condition card totals 190 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.